Medeon Biodesign, Inc. (TPEX:6499)
Taiwan · Delayed Price · Currency is TWD 72.40
-0.60 (-0.82%)
Sep 8, 2026, 1:10 PM CST
Medeon Biodesign Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 428.07 | 419.43 | 292.81 | 196.26 | 298.32 | 68.96 | |
Revenue Growth | 8.54% | 43.24% | 49.19% | -34.21% | 332.61% | -43.96% |
Cost of Revenue | 371.99 | 360.6 | 209.39 | 181.89 | 111.51 | 40.33 |
Gross Profit | 56.08 | 58.83 | 83.41 | 14.38 | 186.81 | 28.63 |
Selling, General & Admin | 213.94 | 194.08 | 203.75 | 185.91 | 153.03 | 108.35 |
Research & Development | 460.31 | 587.19 | 751.87 | 667.46 | 521.62 | 415.87 |
Operating Expenses | 675.6 | 781.34 | 969.03 | 853.94 | 674.65 | 524.22 |
Operating Income | -619.52 | -722.51 | -885.61 | -839.57 | -487.84 | -495.59 |
Interest Expense | -4.24 | -3.68 | -5.56 | -6.64 | -5.21 | -1.03 |
Interest & Investment Income | 8.44 | 7.19 | 20.17 | 19.94 | 10.29 | 6.12 |
Earnings From Equity Investments | - | - | - | 13.54 | 47.69 | 19.66 |
Currency Exchange Gain (Loss) | -2.6 | -2.6 | 14.43 | -6.19 | 15.35 | - |
Other Non Operating Income (Expenses) | 1.73 | 0.19 | 0.2 | 0.39 | 0.34 | -43.07 |
EBT Excluding Unusual Items | -616.19 | -721.42 | -856.37 | -818.53 | -419.38 | -513.91 |
Gain (Loss) on Sale of Investments | 1.72 | 1.72 | -2.28 | -399.15 | -19.73 | - |
Gain (Loss) on Sale of Assets | - | - | - | -13.01 | - | - |
Pretax Income | -614.47 | -719.69 | -858.64 | -1,231 | -439.12 | -513.91 |
Income Tax Expense | -0.09 | -0.35 | 11.88 | 39.29 | 57.79 | 72.46 |
Earnings From Continuing Operations | -614.38 | -719.34 | -870.52 | -1,270 | -496.9 | -586.36 |
Earnings From Discontinued Operations | - | - | - | - | - | 2,618 |
Net Income to Company | -614.38 | -719.34 | -870.52 | -1,270 | -496.9 | 2,031 |
Minority Interest in Earnings | 55.85 | 51.28 | 65.01 | 65.36 | 63.14 | 46.75 |
Net Income | -558.53 | -668.06 | -805.51 | -1,205 | -433.76 | 2,078 |
Net Income to Common | -558.53 | -668.06 | -805.51 | -1,205 | -433.76 | 2,078 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 95 | 92 | 92 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 95 | 92 | 92 | 92 | 92 | 92 |
Shares Change | 2.70% | 0.21% | 0.11% | 0.02% | -0.07% | 0.48% |
EPS (Basic) | -5.89 | -7.24 | -8.74 | -13.09 | -4.71 | 22.65 |
EPS (Diluted) | -5.90 | -7.24 | -8.74 | -13.09 | -4.71 | 22.65 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -520.89 | -645.61 | -906.97 | -810.36 | -601.91 | -301.69 |
Free Cash Flow Per Share | -5.50 | -6.99 | -9.84 | -8.80 | -6.54 | -3.28 |
Dividend Per Share | - | - | - | - | 0.476 | 0.794 |
Dividend Growth | - | - | - | - | -40.00% | - |
Gross Margin | 13.10% | 14.03% | 28.49% | 7.32% | 62.62% | 41.52% |
Operating Margin | -144.72% | -172.26% | -302.45% | -427.78% | -163.53% | -718.69% |
Profit Margin | -130.48% | -159.28% | -275.10% | -613.78% | -145.40% | 3013.75% |
Free Cash Flow Margin | -121.68% | -153.93% | -309.75% | -412.90% | -201.77% | -437.51% |
EBITDA | -567.43 | -666.44 | -839.21 | -797.3 | -459.64 | -463.09 |
EBITDA Margin | -132.56% | -158.89% | -286.61% | - | -154.08% | - |
D&A For EBITDA | 52.09 | 56.08 | 46.4 | 42.26 | 28.2 | 32.5 |
EBIT | -619.52 | -722.51 | -885.61 | -839.57 | -487.84 | -495.59 |
EBIT Margin | -144.72% | -172.26% | - | - | -163.53% | - |